BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 30105521)

  • 1. Combined Early and Late [
    Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
    Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
    Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
    Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.
    Rauscher I; Maurer T; Souvatzoglou M; Beer AJ; Vag T; Wirtz M; Weirich G; Wester HJ; Gschwend JE; Schwaiger M; Schottelius M; Eiber M
    Clin Nucl Med; 2016 Sep; 41(9):e397-402. PubMed ID: 27276206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
    Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSA-Stratified Performance of
    Dietlein F; Kobe C; Neubauer S; Schmidt M; Stockter S; Fischer T; Schomäcker K; Heidenreich A; Zlatopolskiy BD; Neumaier B; Drzezga A; Dietlein M
    J Nucl Med; 2017 Jun; 58(6):947-952. PubMed ID: 27908968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
    Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early dynamic imaging in
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; Warwitz B; Scarpa L; Roig LG; Kendler D; von Guggenberg E; Bektic J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):765-775. PubMed ID: 27900519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study.
    Lengana T; van de Wiele C; Lawal I; Maes A; Ebenhan T; Boshomane T; Zeevaart JR; Ankrah A; Mokgoro N; Vorster M; Sathekge M
    Nucl Med Commun; 2018 Feb; 39(2):179-185. PubMed ID: 29257006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
    Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
    Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated
    Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
    Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Test-Retest Measurement of
    Pollard JH; Raman C; Zakharia Y; Tracy CR; Nepple KG; Ginader T; Breheny P; Sunderland JJ
    J Nucl Med; 2020 Aug; 61(8):1145-1152. PubMed ID: 31806776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
    Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
    Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter Prospective Clinical Trial of
    McCarthy M; Francis R; Tang C; Watts J; Campbell A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.